Literature DB >> 20435381

[Use of intravenous iron infusion in a gastroenterology day hospital: Indications, dosage and adverse effects].

Angelina Dosal1, Xavier Calvet, Laura Moreno, María López, Ariadna Figuerola, Miquel Angel Ruíz, David Suárez, Emili Gené, Mireia Miquel, Albert Villoria.   

Abstract

UNLABELLED: There are no data in the literature on the use of intravenous iron infusion in gastroenterology day hospitals.
OBJECTIVE: To determine the indications, dosage and tolerance of intravenous iron infusion in outpatients attending a gastroenterology day hospital.
MATERIAL AND METHODS: We retrospectively reviewed the medical records of patients who received intravenous iron infusion between August 2007 and July 2008. The indications, dosage, transfusion requirements, adverse effects and patients' clinical and laboratory data were recorded.
RESULTS: During the study period, 111 patients (41% women, with a mean age of 63.8 ± 18 years) received intravenous iron infusions. The main causes of anemia indicating iron administration were portal hypertensive gastropathy (n=55), inflammatory bowel disease (n=22) and intestinal angiodysplasia (n=12). The patients received a total of 557 iron infusions with a mean dose of 1033 mg iron per patient. There were no adverse effects. Despite the treatment, 46 patients required transfusion. Iron and transfusion requirements and mortality were significantly higher in patients with liver cirrhosis than in the remainder of the study group.
CONCLUSION: Intravenous iron therapy is frequently used in the gastroenterology day hospital. Most infusions were administered in patients with chronic iron loss. Patients with liver cirrhosis had the most severe anemia and underlying disease and the highest mortality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20435381     DOI: 10.1016/j.gastrohep.2010.02.011

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  1 in total

1.  Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency.

Authors:  Xavier Calvet; Miquel Àngel Ruíz; Angelina Dosal; Laura Moreno; Maria López; Ariadna Figuerola; David Suarez; Mireia Miquel; Albert Villoria; Emili Gené
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.